| Name | BC-1215 |
| Description | BC-1215 is an inhibitor of F-box protein 3 (FBXO3, a ubiquitin E3 ligase component, IC50=0.9 μg/mL for IL-1β release). |
| Animal Research | Tested effects of administration of BC-1215 in a model of a cecal ligation and puncture (CLP)-induced sepsis. Mice with CLP had significantly increased cytokine release compared to sham treated mice. BC-1215 treatment significantly attenuated CLP-induced secretion of all three circulating pro-inflammatory cytokines in mice . BC-1215 also decreased bacterial counts in the CLP model and modestly produced inhibition of bacterial growth using Kirby Bauer testing |
| In vivo | A small molecule inhibitor BC-1215 argeting Fbxo3 was sufficient to lessen severity of cytokine-driven inflammation in several murine disease models. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (2.53 mM), Sonication is recommended. DMSO : 3.95 mg/mL (10.01 mM), Sonication is recommended.
|
| Keywords | U937 cells | TRAF | PBMC cells | MLE cells | Ligands for E3 Ligase | LigandforE3Ligase | Ligand for E3 Ligase | Inhibitor | inhibit | inflammation | FBXO3 | F-box protein 3 (Fbxo3) | E3 ligase-recruiting Moiety | BC-1215 | BC1215 | BC 1215 |
| Inhibitors Related | Lenalidomide-Br | Pomalidomide 4'-alkylC3-acid | PT-179 | (S)-Thalidomide | Thalidomide | (S,R,S)-AHPC | Pomalidomide | Amino-PEG1-C2-acid | Lenalidomide | (S,R,S)-AHPC hydrochloride | 5-Aminothalidomide | Thalidomide 5-fluoride |
| Related Compound Libraries | Bioactive Compound Library | Ubiquitination Compound Library | Inhibitor Library | NO PAINS Compound Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Anti-COVID-19 Compound Library |